title: Ustekinumab: a novel therapeutic option in Crohn's disease.
abstract: Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23.
  
  
  
  This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world.
  
  
  
  Current literature strongly supports the fact that ustekinumab is clinically efficacious and reasonably safe for induction and maintenance of remission in moderate-to-severe Crohn's disease.
authors.affiliation: a Department of Gastroenterology , Christian Medical College , Vellore , India.|b NIHR Nottingham Digestive Diseases Biomedical Research Unit , Nottingham University Hospitals NHS Trust and University of Nottingham , Nottingham , UK.
authors.forename: E G
authors.initials: EG
authors.lastname: Simon
authors.affiliation: b NIHR Nottingham Digestive Diseases Biomedical Research Unit , Nottingham University Hospitals NHS Trust and University of Nottingham , Nottingham , UK.
authors.forename: S
authors.initials: S
authors.lastname: Samuel
authors.affiliation: c Department of Medicine and IBD Clinic , University of Calgary , Calgary , Canada.
authors.forename: S
authors.initials: S
authors.lastname: Ghosh
authors.affiliation: b NIHR Nottingham Digestive Diseases Biomedical Research Unit , Nottingham University Hospitals NHS Trust and University of Nottingham , Nottingham , UK.
authors.forename: G W
authors.initials: GW
authors.lastname: Moran
mesh_terms: D057176:Compassionate Use Trials; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D018664:Interleukin-12 / Q000276:immunology; D053759:Interleukin-23 / Q000276:immunology; D000069549:Ustekinumab / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D053759:Interleukin-23; D018664:Interleukin-12; D000069549:Ustekinumab
keywords: Anti-TNF agents; Crohn’s disease; biologic therapy; ustekinumab